The impact of extensive intraductal component (EIC) on the genomic risk of recurrence in early hormone receptor positive breast cancer
-
Published:2024-10
Issue:
Volume:77
Page:103777
-
ISSN:0960-9776
-
Container-title:The Breast
-
language:en
-
Short-container-title:The Breast
Author:
Bar YaelORCID,
Bar Kfir,
Feldman Didi,
Dror Judith Ben-,
Shahoha Meishar,
Lerner Shir,
Shachar Shlomit Strulov,
Weiss-Meilik Ahuva,
Dershowitz Nachum,
Wolf Ido,
Sonnenblick Amir
Reference38 articles.
1. Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review;Łukasiewicz;Cancers,2021
2. Ductal carcinoma in situ: to treat or not to treat, that is the question;on behalf of the Precision team;Br. J. Cancer,2019
3. Cancer outcomes in DCIS patients without locoregional treatment;Ryser;JNCI J. Natl. Cancer Inst.,2019
4. Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ;Maxwell;Eur J Surg Oncol,2018
5. Continued local recurrence of carcinoma 15–25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy;Page;Cancer,1995